New Approach to Evaluating Cases with Rheumatic Reactions to Cancer Immunotherapy

New approach to evaluating cases with rheumatic reactions to cancer immunotherapy

The prevalence and severity of rheumatic adverse reactions in cancer immunotherapy is significantly underestimated, due to the lack of standardized screening protocols for malignancies in patients with autoimmune disorders. In response to the need for data collection and diagnostic criteria, researchers have developed a trans-disciplinary approach to safeguard those patients at risk.

New SHRO Study: Consider Cases with Rheumatic Reactions to Cancer Immunotherapy

Philadelphia, PA – May 19, 2025 — The prevalence and severity of rheumatic adverse reactions in cancer immunotherapy is significantly underestimated, due to the lack of standardized screening protocols for malignancies in patients with autoimmune disorders. In response to the need for data collection and diagnostic criteria, researchers have developed a trans-disciplinary approach to safeguard those patients at risk.  The paper, “Onco-Rheumatolo…